1. Home
  2. FULC vs BZAI Comparison

FULC vs BZAI Comparison

Compare FULC & BZAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.69

Market Cap

281.1M

Sector

Health Care

ML Signal

N/A

Logo Blaize Holdings Inc.

BZAI

Blaize Holdings Inc.

N/A

Current Price

$0.12

Market Cap

268.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FULC
BZAI
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.1M
268.9M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
FULC
BZAI
Price
$3.69
$0.12
Analyst Decision
Hold
Buy
Analyst Count
5
2
Target Price
★ $3.67
$1.75
AVG Volume (30 Days)
1.2M
★ 1.9M
Earning Date
11-12-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 43.43
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$9.24
Revenue Next Year
N/A
$168.89
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.83
$0.12
52 Week High
$15.74
$2.82

Technical Indicators

Market Signals
Indicator
FULC
BZAI
Relative Strength Index (RSI) 45.53 24.32
Support Level $3.62 N/A
Resistance Level $3.81 $0.23
Average True Range (ATR) 0.06 0.02
MACD -0.00 0.00
Stochastic Oscillator 7.69 1.28

Price Performance

Historical Comparison
FULC
BZAI

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

About BZAI Blaize Holdings Inc.

Blaize Holdings Inc provides transformative artificial intelligence (AI)-enabled edge computing solutions comprised of both its proprietary hardware and software, and third-party hardware solutions. Its portfolio includes programmable AI processors in various form factors, which can be deployed across sectors such as smart cities, defense, retail, and enterprise markets. The company operates as a single operating and reportable segment. The majority of the company's revenue is derived from Hardware revenue, which includes the sale of its semiconductor products and/or third-party hardware products that support semiconductor products through various supply agreements. Geographically, it generates the maximum revenue from China.

Share on Social Networks: